MedTrace Logo

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA

NCT02509026 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2020-06-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.

Conditions

  • Spondylitis, Ankylosing

Interventions

BIOLOGICAL

Etanercept

50 mg subcutaneous, once weekly, 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-24
Primary Completion
2019-05-28
Completion
2019-09-06

Countries

  • United States
  • Australia
  • Belgium
  • Colombia
  • Czechia
  • Finland
  • France
  • Germany
  • Hungary
  • Netherlands
  • Poland
  • Spain
  • Sweden
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02509026 on ClinicalTrials.gov